Status
Conditions
Treatments
About
PrismaLung+ is indicated to provide extracorporeal carbon dioxide removal (ECCO2R) as a stand-alone therapy or in combination with continuous renal replacement therapy (CRRT). This study is intended for patients with increased levels of Carbon Dioxide (CO2) in their blood and ≥ 18 years old, and will treat patients with mild or moderate acute respiratory distress syndrome (ARDS) using PrismaLung+. The study will assess tidal volume reduction and confirm the safety of PrismaLung+.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient age is ≥ 18 years old
Patient is expected to receive ECCO2R for a minimum of 24 hours
Patient has mild or moderate ARDS according to the Berlin definition:
Written informed consent to participate in the study from the patient, if possible, or from the identified authorized representative if the patient is unable to provide consent.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
60 participants in 1 patient group
Loading...
Central trial contact
Baxter Clinical Trials Disclosure Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal